Amgen Inc.
Amgen Inc. develops, manufactures, and delivers human therapeutics worldwide. The companys principal products treat various conditions including psoriasis, arthritis, osteoporosis, and cancer. Additional products include Repatha for cardiovascular risk reduction and Neulasta for neutropenia prevention. Amgen serves healthcare providers, pharmaceutical wholesale distributors, and direct-to-consumer channels. The company has collaborations with AstraZeneca, Novartis, UCB, Kyowa Kirin, and BeiGene. Founded in 1980, Amgen is headquartered in Thousand Oaks, California.
Overview
Strengths
- Shows the financial signature of a durable competitive advantage (economic moat): consistently high returns on capital, returns well above its cost of capital and an asset-light, cash-generative model.
- Return on invested capital has stayed above 15% in 6 of the last 7 years (latest 15.7%), a hallmark of a durable competitive advantage.
- Creates economic value: ROIC of 15.7% against a cost of capital (WACC) of 6.3%, a spread of 9.5 percentage points.
- Asset-light, cash-generative model: capital expenditure takes only 3.6% of revenue and free cash flow was positive in each of the last 7 years.
- Consistent growth: revenue has compounded at 7.8% a year over 6 years, rising every year.
- Improving fundamentals over the last year: return on assets up 4.1 points, gross margin up 5.7 points and asset turnover up 11.5%.
Weaknesses
- Our discounted cash flow target price (194.32 USD) is 58% below the current price.
- Valued at a premium to its Drug Manufacturers - General peers: P/E 32.2x vs. a median of 22.1x and P/FCF 30.6x vs. a median of 20.8x.
- More expensive than its own history: P/E 32.2x vs. a historical average of 21.8x and P/FCF 30.6x vs. a historical average of 16.1x.
Key Financial Data